Long-acting HIV prevention meds: 10 Breakthrough Technologies 2025 – MIT Technology Review

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.
Gilead Sciences, GSK, ViiV Healthcare
1 to 3 years
In June 2024, results from a trial of a new medicine to prevent HIV were announced—and they were jaw-dropping. Lenacapavir, a treatment injected once every six months, protected over 5,000 girls and women in Uganda and South Africa from getting HIV. And it was 100% effective.
Explore the full 2025 list of 10 Breakthrough Technologies.
The drug, which is produced by Gilead, has other advantages. We’ve had effective pre-exposure prophylactic (PrEP) drugs for HIV since 2012, but these must be taken either daily or in advance of each time a person is exposed to the virus. That’s a big ask for healthy people. And because these medicines also treat infections, there’s stigma attached to taking them. For some, the drugs are expensive or hard to access. In the lenacapavir trial, researchers found that injections of the new drug were more effective than a daily PrEP pill, probably because participants didn’t manage to take the pills every day.
 In 2021, the US Food and Drug Administration approved another long-acting injectable drug that protects against HIV. That drug, cabotegravir, is manufactured by ViiV Healthcare (which is largely owned by GSK) and needs to be injected every two months. But despite huge demand, rollout has been slow.   
CRISPR is being used in an experimental effort to eliminate the virus that causes AIDS.
Scientists and activists hope that the story will be different for lenacapavir. So far, the FDA has approved the drug only for people who already have HIV that’s resistant to other treatments. But Gilead has signed licensing agreements with manufacturers to produce generic versions for HIV prevention in 120 low-income countries. 
In October, Gilead announced more trial results for lenacapavir, finding it 96% effective at preventing HIV infection in just over 3,200 cisgender gay, bisexual, and other men, as well as transgender men, transgender women, and nonbinary people who have sex with people assigned male at birth. 
The United Nations has set a goal of ending AIDS by 2030. It’s ambitious, to say the least: We still see over 1 million new HIV infections globally every year. But we now have the medicines to get us there. What we need is access. 
Human cases in the US are on the rise and the virus is turning up in cows and dairy products. Luckily, we have some vaccines ready to go if needed.
The models can be used to plan surgeries and in the future could be used to help trial new drugs.
Around 135 transplants have been performed, but it's probably too soon to offer the procedure to trans women.
The ever-increasing use of GLP-1 agonists is uncovering clues about what else they can do.
Discover special offers, top stories, upcoming events, and more.
Thank you for submitting your email!
It looks like something went wrong.
We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.

© 2025 MIT Technology Review

source
This is a newsfeed from leading technology publications. No additional editorial review has been performed before posting.